Adicet Bio, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Adicet Bio, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-06-30 was 1.00 shares.
- Adicet Bio, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-03-31 was 0.00 shares.
- Adicet Bio, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-12-31 was 50.00 shares.
- Adicet Bio, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-09-30 was 0.00 shares.
- Adicet Bio, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 50.00 shares, a 99.95% decline from fiscal 2024.
- Adicet Bio, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 92.28K shares, a 9655.07% increase from fiscal 2023.
- Adicet Bio, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 946.00 shares, a 99.25% decline from fiscal 2022.
- Adicet Bio, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 126.18K shares, a 88.79% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2026-06-30 | 1.00 shares 10-Q · filed 2026-08-05 | 51.00 shares derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | 0.00 shares 10-Q · filed 2026-05-13 | 50.00 shares derived: sum of 4 quarters · filed 2026-05-13 |
| 2025-12-31 | 50.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | 50.00 shares 10-K · filed 2026-03-12 |
| 2025-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | 0.00 shares derived: sum of 4 quarters · filed 2025-11-05 |
| 2025-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | 0.00 shares derived: sum of 4 quarters · filed 2025-08-07 |
| 2025-03-31 | 0.00 shares 10-Q · filed 2025-05-06 | 4.00K shares derived: sum of 4 quarters · filed 2025-05-06 |
| 2024-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | 92.28K shares 10-K · filed 2025-03-06 |
| 2024-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | 92.28K shares derived: sum of 4 quarters · filed 2024-11-06 |
| 2024-06-30 | 4.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | 92.28K shares derived: sum of 4 quarters · filed 2024-08-13 |
| 2024-03-31 | 88.28K shares 10-Q · filed 2024-05-14 | 88.52K shares derived: sum of 4 quarters · filed 2024-05-14 |
| 2023-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | 946.00 shares 10-K · filed 2024-03-19 |
| 2023-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | 76.95K shares derived: sum of 4 quarters · filed 2023-11-08 |
| 2023-06-30 | 233.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | 99.17K shares derived: sum of 4 quarters · filed 2023-08-09 |
| 2023-03-31 | 713.00 shares 10-Q · filed 2023-05-09 | 116.79K shares derived: sum of 4 quarters · filed 2023-05-09 |
| 2022-12-31 | 76.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | 126.18K shares 10-K · filed 2023-03-15 |
| 2022-09-30 | 22.22K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | 628.87K shares derived: sum of 4 quarters · filed 2022-11-08 |
| 2022-06-30 | 17.85K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | 719.70K shares derived: sum of 4 quarters · filed 2022-08-10 |
| 2022-03-31 | 10.10K shares 10-Q · filed 2022-05-12 | 741.45K shares derived: sum of 4 quarters · filed 2022-05-12 |
| 2021-12-31 | 578.70K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | 1.13M shares 10-K · filed 2022-03-15 |
| 2021-09-30 | 113.05K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | |
| 2021-06-30 | 39.60K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | |
| 2021-03-31 | 393.99K shares 10-Q · filed 2021-05-17 | |
| 2020-12-31 | 210.75K shares 10-K · filed 2021-03-12 | |
| 2019-12-31 | 14.79K shares 10-K · filed 2021-03-12 | |
| 2018-12-31 | 123.95K shares 10-K · filed 2021-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |